viewLexaria Bioscience Corp.

Lexaria Bioscience welcomes four new experts to advisory board to guide ongoing research

The Kelowna-headquartered company has developed and out-licenses its disruptive DehydraTECH technology

Lexaria has expanded its advisory board

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) has added four experts to its scientific advisory board to guide the firm's ongoing and future R&D (research and development) programs.

The Kelowna-headquartered company has developed and out-licenses its disruptive DehydraTECH technology that promotes lower dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

READ: Lexaria Bioscience gains after announcing cannabinoid R&D project is underway

Essentially, the tech allows cannabidiol (CBD) and other oils to be dehydrated into an odourless, tasteless powder and mixed into other substances.

Dr. Dwayne Godwin is a neuroscientist with extensive experience in the pharmacology of the brain and translational interests in the physiological basis and neuroimaging of brain injury, alcohol abuse, epilepsy and seizure, Alzheimer's and PTSD (post-traumatic stress disorder).

Meanwhile, Dr. Terry Blumenthal is professor, psychology and neuroscience, at Wake Forest University in North Carolina. His research interests include psychophysiology, research design and methodology, PTSD, information processing, schizophrenia, and developmental neuroscience.

Dr. Matthew Fraser has extensive experience in urological and gastrointestinal neuroscience preclinical research, development of research models and methods, experimental design, and early clinical development in both academic and industry settings.

Finally, Dr. Carla Lema Tome is an industry consultant and is widely published on topics including but not limited to cellular and molecular neuroscience, inflammation, neurodegeneration, and cancer biology.

Extensive experience

She has extensive experience in global medical and commercial strategy consulting with emphasis on integrated clinical development, asset and portfolio strategy, launch planning payer research and payer value communications

"Lexaria Bioscience Corp is very pleased to welcome these accomplished experts to our advisory board, who can provide critical scientific guidance to Lexaria's ongoing and future R&D programs," said Chris Bunka, CEO at Lexaria.

"Lexaria is building towards becoming one of the world's leaders in drug delivery technology and our most recent Advisors can assist in achieving that goal."

Contact Giles at [email protected]

Follow him on Twitter@Gile74

Quick facts: Lexaria Bioscience Corp.

Price: 0.67 CAD

Market: CSE
Market Cap: $54.08 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...



Buds & Duds: Cannabis stocks hold steady; Lexaria rises on amended agreement...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, inched 0.2% higher at 122.9 points. Elsewhere, the OTCQX Cannabis index lost 0.2% to 489.3 points. Buds today are Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), Curaleaf Holdings Inc...

3 weeks, 5 days ago

2 min read